Filing Flows › Gyre Therapeutics (GYRE) › Free cash flow
Gyre Therapeutics (GYRE) free cash flow by quarter
Gyre Therapeutics' free cash flow was $3.0M in Q1 2026 (first quarter 2026), -25% from Q3 2025. Over the last 3 quarters it ranged from $1.8M (Q2 2025) to $4.0M (Q3 2025).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q1 2026 | $3.0M | -25% | — |
| Q3 2025 | $4.0M | +119% | — |
| Q2 2025 | $1.8M | — | — |
Q1 2026 at a glance
Gyre Therapeutics, Q1 2026: revenue $22.5M (+2% year over year), operating margin -41.5%, net loss $9.9M, operating cash flow $3.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Gyre Therapeutics' free cash flow?
Gyre Therapeutics' free cash flow was $3.0M in Q1 2026 (first quarter 2026), -25% from Q3 2025.
How has Gyre Therapeutics' free cash flow changed?
Over the last 3 quarters it ranged from $1.8M (Q2 2025) to $4.0M (Q3 2025).